Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Molecular Partners (MOLN)
LifeSci Capital analyst Charles Zhu maintained a Buy rating on Molecular Partners today and set a price target of $12.00. The company’s shares closed last Friday at $3.77, close to its 52-week low of $3.32.
According to TipRanks.com, Zhu is a 5-star analyst with an average return of 23.4% and a 56.5% success rate. Zhu covers the Healthcare sector, focusing on stocks such as Context Therapeutics, Protara Therapeutics, and Revolution Medicines.
Currently, the analyst consensus on Molecular Partners is a Strong Buy with an average price target of $11.00.
